CD274 and neoplasm: PD-1 and programmed death ligand-1 (PD-L1) form the PD-1/PD-L1 complex, which plays a role in down-regulating T-cell activity, which may result in faster tumour growth and poor prognosis in the clinical setting of anti-cancer therapy.